Objective {#Sec1}
=========

To investigate the efficacy of polymyxin-B direct hemoperfusion (PMX-DHP) in terms of improving clinical conditions and life prognosis in severe sepsis cases.

SUBJECTS AND METHODS {#Sec2}
====================

The subjects were 88 cases admitted to our hospital ICU between April 2010 and July 2014 with the diagnosis of severe septic shock requiring continuous norepinephrine injection (Cathecholamine Index≧10). We investigated PMX-DHP efficacy by retrospectively comparing 63 cases that underwent PMX-DHP with 25 cases that did not.

Results {#Sec3}
=======

The two groups did not differ significantly in age, APACHE II score, SOFA score, infection focus, and bacterial species. The 28-day mortality was 32% in the PMX-DHP group and 40% in the non-PMX-DHP group, but this difference was not significant. The ⊿CAI (the change in Cathecholamine Index 24 hours after PMX-DHP administration) and the infusion volume 24 hours after PMX-DHP administration were significantly different between the two groups. Multivariate analysis identified ⊿CAI and SOFA score as independent prognostic factors. Sub-analysis showed no significant difference in 28-day mortality in sepsis cases involving the lower-gastrointestinal tracts, but a trend for improvement in 28-day mortality was observed in sepsis cases where the infection focus could not be removed, such as pneumonia, and in severe sepsis cases whose APACHE II score exceeded 25.

Conclusions {#Sec4}
===========

PMX-DHP may improve life prognosis of septic shock cases under certain conditions. We have to clarify the indication criteria for PMX-DHP and accumulate data by additional investigations of severe septic cases to pursue the possibilities for further improvements in life prognosis.
